B lymphocytes as effector cells in the immunotherapy of cancer

Over the years, the role of B cells in the host immune response to malignancy has been overshadowed by our focus on T cells. Nevertheless, B cells play important roles as antigen‐presenting cells and in the production of antibodies. Furthermore, B cells can function as effector cells that mediate tumor destruction on their own. This review will highlight the various functions of B cells that are involved in the host response to tumor. J. Surg. Oncol. 2012;105:431–435. © 2011 Wiley Periodicals, Inc.

[1]  A. Chang,et al.  Adoptive Transfer of Tumor Reactive B Cells Confers Host T-Cell Immunity and Tumor Regression , 2011, Clinical Cancer Research.

[2]  T. Tedder,et al.  B Cells Are Required for Optimal CD4+ and CD8+ T Cell Tumor Immunity: Therapeutic B Cell Depletion Enhances B16 Melanoma Growth in Mice , 2010, The Journal of Immunology.

[3]  A. Chang,et al.  In Vivo Sensitized and In Vitro Activated B Cells Mediate Tumor Regression in Cancer Adoptive Immunotherapy1 , 2009, The Journal of Immunology.

[4]  T. Lebien,et al.  B lymphocytes: how they develop and function. , 2008, Blood.

[5]  C. Bacchelli,et al.  Translational Mini‐Review Series on Immunodeficiency:
Molecular defects in common variable immunodeficiency , 2007, Clinical and experimental immunology.

[6]  F. Ronchese,et al.  Resting B Cells Suppress Tumor Immunity via an MHC Class-II Dependent Mechanism , 2007, Journal of immunotherapy.

[7]  S. Inoue,et al.  Inhibitory effects of B cells on antitumor immunity. , 2006, Cancer research.

[8]  S. Ko,et al.  CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. , 2006, Cancer research.

[9]  J. Berzofsky,et al.  Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain. , 2006, Cancer research.

[10]  F. Lund,et al.  Cutting Edge: The Development of IL-4-Producing B Cells (B Effector 2 Cells) Is Controlled by IL-4, IL-4 Receptor α, and Th2 Cells1 , 2005, The Journal of Immunology.

[11]  A. Divekar,et al.  Increased rejection of primary tumors in mice lacking B cells: Inhibition of anti‐tumor CTL and TH1 cytokine responses by B cells , 2005, International journal of cancer.

[12]  S. Peng,et al.  Regulation of IFN-γ Production by B Effector 1 Cells: Essential Roles for T-bet and the IFN-γ Receptor1 , 2005, The Journal of Immunology.

[13]  G. Vanham,et al.  Ex vivo induction of viral antigen‐specific CD8+ T cell responses using mRNA‐electroporated CD40‐activated B cells , 2005, Clinical and experimental immunology.

[14]  T. Griffith,et al.  Human B Cells Express Functional TRAIL/Apo-2 Ligand after CpG-Containing Oligodeoxynucleotide Stimulation1 , 2004, The Journal of Immunology.

[15]  J. Kaplan,et al.  Enhanced Efficacy of Melanoma Vaccines in the Absence of B Lymphocytes , 2004, Journal of immunotherapy.

[16]  S. Grupp,et al.  RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. , 2004, Blood.

[17]  P. Hwu,et al.  CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. , 2003, Cancer research.

[18]  K. Anderson,et al.  Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. , 2002, Blood.

[19]  S. Swain,et al.  Reciprocal regulation of polarized cytokine production by effector B and T cells , 2000, Nature Immunology.

[20]  M. Moser,et al.  B Lymphocytes Regulate Dendritic Cell (Dc) Function in Vivo , 2000, The Journal of experimental medicine.

[21]  D. Lo,et al.  Influence of lymphocytes on the presence and organization of dendritic cell subsets in the spleen. , 1999, Journal of immunology.

[22]  A. Chapoval,et al.  Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. , 1998, Journal of immunology.

[23]  J. Gribben,et al.  CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. , 1997, The Journal of clinical investigation.

[24]  K. Tamada,et al.  Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2 , 1995, Cancer Immunology, Immunotherapy.

[25]  M. Harada,et al.  The antitumor activity induced by the in vivo administration of activated B cells bound to anti-CD3 monoclonal antibody. , 1995, Cellular immunology.

[26]  H. Schreiber,et al.  CD4+ AND B LYMPHOCYTES IN TRANSPLANTATION IMMUNITY: II. AUGMENTED REJECTION OF TUMOR ALLOGRAFTS BY MICE LACKING B CELLS , 1993, Transplantation.

[27]  Ornella Parolini,et al.  Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia , 1993, Cell.

[28]  B. Blomberg,et al.  Nuclear disintegration of target cells by killer B lymphocytes from tumor‐bearing mice , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  J. Sprent,et al.  T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes. , 1987, Journal of immunology.

[30]  C. Janeway,et al.  The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. , 1987, Journal of immunology.

[31]  Antonio Lanzavecchia,et al.  Antigen-specific interaction between T and B cells , 1985, Nature.

[32]  P. Brodt,et al.  Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. , 1978, Journal of immunology.

[33]  M. Cooper,et al.  THE FUNCTIONS OF THE THYMUS SYSTEM AND THE BURSA SYSTEM IN THE CHICKEN , 1966, The Journal of experimental medicine.

[34]  M. Cooper,et al.  Delineation of the Thymic and Bursal Lymphoid Systems in the Chicken , 1965, Nature.

[35]  A. Fagraeus.  Plasma Cellular Reaction and its Relation to the Formation of Antibodies in vitro , 1947, Nature.

[36]  M. Ehrenstein,et al.  The 'short' history of regulatory B cells. , 2008, Trends in immunology.

[37]  S. Peng,et al.  Regulation of IFN-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor. , 2005, Journal of immunology.

[38]  A. Bhan,et al.  A Case for Regulatory B Cells , 2005 .

[39]  近藤 英生.  Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells , 2003 .

[40]  T. Blankenstein,et al.  B cells inhibit induction of T cell-dependent tumor immunity , 1998, Nature Medicine.

[41]  D. Vetrie,et al.  The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases , 1993, Nature.

[42]  P. De Baetselier,et al.  Defective induction of antigen‐reactive proliferating T cells in B cell‐deprived mice , 1981, European journal of immunology.